Subscribe for free to our flagship newsletter, CDR: This Week in Retail, for news and insights from the voice of retail pharmacy.

Skip to content

Lupin releases budesonide inhalation suspension

Lupin announced the launch of its budesonide inhalation suspension, 0.5 mg/2 mL single-dose ampules in the U.S. market, having received an approval from the United States Food and Drug Administration earlier. Lupin’s budesonide inhalation suspension, 0.

Table of Contents

BALTIMORE — Lupin announced the launch of its budesonide inhalation suspension, 0.5 mg/2 mL single-dose ampules in the U.S. market, having received an approval from the United States Food and Drug Administration earlier.

Lupin’s budesonide inhalation suspension, 0.5 mg/2 mL single-dose ampules is a generic version of AstraZeneca Pharmaceuticals LP’s Pulmicort Respules Inhalation Suspension, 0.5 mg/2 mL. It is indicated for the maintenance treatment of asthma and as prophylactic therapy in children from 12 months to 8 years of age.

Budesonide inhalation suspension, 0.5 mg/2 mL single-dose Ampules had annual sales of approximately USD 385.4 million in the US (IMS MAT March 2019).

Comments

Latest